Assessment of quality of life in patients with chronic myeloid leukaemia on diagnosis and after treatment with imatinib

Aleksandra Anna Łanocha, Barbara Zdziarska, Arkadiusz Kazimierczak


Introduction: The aim of the study was to assess the quality of life (QL) in patients with chronic myeloid leukaemia (CML) on diagnosis, and after 1 month and 12 months of treatment with imatinib, and to identify therapeutic elements which significantly lower the QL in the patients.

Materials and methods: Assessment of QL was performed in adult patients diagnosed with CML hospitalized in the Department of Haematology, Department of Chemotherapy, and the Haematology Outpatient Clinic, Pomeranian Medical University in Szczecin (Poland). Quality of life was assessed with 2 questionnaires: EORTC QLQ-C30 and EQ-5D, while symptoms of depression were measured using the CES-D questionnaire. Quality of life was analyzed at 3 time points: on diagnosis (A1), after 1 month (A2), and after 12 months of therapy (A3). All groups of patients were treated with imatinib.

Results: Emotional functioning and global health status and subjective QL significantly improved from A1 to A3. Patients reported significantly less fatigue and pain. Symptoms of depression significantly reduced during treatment. The group of patients caring for others in serious illness had reported a higher index of depression. Patients without any academic degree or extra qualifications, and the group of patients caring for others in serious illness, had reported significantly lower cognitive functioning.

Conclusions: Measurement of various aspects of QL using the EORTC QLQ-C30 and EQ-5D questionnaires showed significant improvements after the 1st month of treatment compared to the state at diagnosis of CML. Due to high levels on the CES-D Depression Scale patients with CML do require constant psychological assistance and in some cases also psychiatric help.


chronic myeloid leukaemia; quality of life; depression, imatinib

Full Text:

PDF (Język Polski)


Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 2013;37:206-13.

Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported out-comes. Crit Rev Oncol Hematol 2012;81:123-35.

Saussele S, Pfirrmann M. Clinical trials in CML. Curr Hematol Malig Rep 2012;7:109-15.

Siddiqui F, Kachnic LA, Movsas B. Quality of life outcomes in Oncology. Hematol Oncol Clin North Am 2006;20:165-85.

Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 2011;52(6):1017-23. doi: 10.3109/10428194.2011.560310.

Curran MP, Croom KF, Goa KL. Spotlight on imatinib mesylate in chronic myeloid leukemia. BioDrugs 2004;18:207-10.

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554-60.

Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27:1511-9.

Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, et al. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Ann Hematol 2012;91:1371-81.

Fava C, Moratti A, Dogliotti I, Saglio G, Rege-Cambrin G. Update on emerging treatments for chronic myeloid leukemia. Expert Opin Emerg Drugs 2015;3(31):1-14.

Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. Curr Med Res Opin 2014;30(11):2317-28.

Cella D, Nowinski CJ, Frankfurt D. The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology 2014;87(3):133-47.

Jain P, Das VN, Romjan A, Chaudhary R, Pandey K. Comparative study for the efficacy, safety and quality of life patients of chronic myeloid leukemia treated with imatinib or hydroxyurea. J Res Pharm Pract 2013;2(4):156-61.

Hamerschlak N, de Sauza C, Cornacchioni AL, Pasquini R, Tabak D, Spector N, et al. Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor. Support Care Cancer 2014;22(8):2113-8.

Levitan D. Chronic fatigue limits quality of life in imatinib-treated chronic myeloid leukemia patients. Oncology J 2013. (2.05.2015).

Kamusheve M, Vulchanova T, Georgieva S, Chervenkova N, Krusteva I, Camurjieva A, et al. Study of quality of life and costs for chronic myeloid leukemia patients in Bulgaria. Value Health 2013;16(7):388.

Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health­-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008;44: 1497-506.

Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003;21: 2138-46.

Homewood J, Watson M, Richards SM, Halsey J, Shepherd PC. Treatment of CML using IFN-alpha: impact on quality of life. Hematol J 2003;4-62.

Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-term medical out-comes and quality of life assessmenet of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002;20:2334-43.

Molnár L, Nagy A, Dávid M, Szomor A, Méhes G, Kovács G, et al. Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha. Orv Hetil 2004;145:901-7.

Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 2013;21:1097-103.

Stalfelt AM, Zettervall O. Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon. Leuk Res 1997;21:775-83.

Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012;36-42.

Trask PC, Cella D, Powell C, Reisman A, Whiteley J, Kelly V. Health-related quality of life in chronic myeloid leukemia. Leuk Res 2013;37:9-13.

Prejzner W, Sacha T, Salamanczuk Z, Pieńkowska-Grela B, Haus O, Hellmann A. Standard of diagnostics and therapeutic procedures in patients with chronic myeloid leukemia in Poland In 2007. Acta Haematol Pol 2007;38:107-22.

Zittoun R, Achard S, Ruszniewski M. Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psychooncolology 1999;8:64-73.

Aaronson NK, Ahedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.

EORTC QLQ-C30. (6.11.2009).

Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9.

Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/Retest Study of the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Clin Oncol 1995;13:1249-54.

King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555-67.

Sprangers MAG, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. Qual Life Res 1998;7:291-300.

Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: A European perspective. Dordrecht, Boston, London: Kluwer Academic Publishers; 2003.

Cole SR, Kawachi I, Maller SJ, Berkman LF. Test of item-response bias in the CES-D scale: experience from the New Haven EPESE Study. J Clin Epidemiol 2000;53:285-9.

Radloff LS. The CES-D Scale. A self-report depression scale for research in the general population. SAGE J 1977. (6.11.2009).

Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin ThR. Quality of life in long-term, disease-free survivors of breast cancer: follow-up study. J Natl Cancer Inst 2002;94(1):39-49.


Copyright (c) 2017 Aleksandra Anna Łanocha, Barbara Zdziarska, Arkadiusz Kazimierczak

License URL: